

**Question for written answer E-009856/2015  
to the Commission**  
Rule 130  
**Lola Sánchez Caldentey (GUE/NGL)**

Subject: Indian pharmaceutical industry

Indian generic medicinal products play a vital part in ensuring that thousands of people have access to affordable medical treatment.

The organisation Médecins sans Frontières (MSF) is warning that the proposed Regional Comprehensive Economic Partnership is intensifying the pressure being brought to bear on India to introduce more stringent rules on pharmaceutical patents. This is not the only trade agreement to jeopardise the Indian medical industry; MSF has also complained about the pressure being exerted by a range of countries – including European Union Member States – through bilateral treaties.

According to the studies available to the Commission, how will the world supply of medicinal products be affected if India's ability to produce generics is restricted?